| Therapeutic | Zemocimig |
| Target 1 | F9a |
| Heavy Chain 1 | QVQLVESGGGLVQPGGSLRLSCAASGFTFSYYDIQWVRQAPGKGLEWVSSISPSGQSTYYRREVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARRTGREEGGWIFDYWGQGTLVTVSS |
| Light Chain 1 | EIVLTQSPATLSVSPGERATLSCRASRSVRRELAWYQQKPGQAPELLIYGASTRETGIPARFSGSGSGTDFTLTINSLEAEDAATYYCQQYRDPPGTFGGGTKVEIK |
| 100% seqID Fv 1 Structure | 8guz [Fvs: AB, CD], 8gv0 [Fvs: AB, CD, EF, GH] |
| 99% seqID Fv 1 Structure | None |
| 95-98% seqID Fv 1 Structure | None |
| Target 2 | F10 |
| Heavy Chain 2 | QVQLVQSGSELKKPGASVKVSCKASGYTFTQNNMDWVRQAPGQGLEWMGDINTRSGGVIYNEEFQDRLIMTVDKSTDTAYMELSSLRSEDTATYHCARRKSYGYYLDVWGEGTLVTVSS |
| Light Chain 2 | SYVLTQPVSVSVALGQTATITCEGEQIGSKEVHWYHQRPGQAPILVMFRDARRPSGIPERLSGSNSGNTASLTISGAEAGDEGDYYCQVWDSSSYTVFGGGTKVTVV |
| 100% seqID Fv 2 Structure | 8gv1 [Fvs: AB], 8gv2 [Fvs: AB] |
| 99% seqID Fv 2 Structure | None |
| 95-98% seqID Fv 2 Structure | None |
| 100% seqID Structure [Fv 1] | 8gv0 [Fvs: AB, CD, EF, GH] |
| 100% seqID Structure [Fv 1] | 8guz [Fvs: AB, CD] |
| 100% seqID Structure [Fv 2] | 8gv1 [Fvs: AB] |
| 100% seqID Structure [Fv 2] | 8gv2 [Fvs: AB] |
Follow these links to our prediction tools:
| Format | Bispecific mAb |
| Isotype | G4;G4 |
| Highest Clinical Trial (Feb '25) | TBC |
| Estimated Status (Feb '25) | TBC |
| Recorded Developmental Technology | TBC |
| INN Year Proposed | 2025 |
| INN Year Recommended | None |
| Companies Involved | TBC |
| Conditions Approved | TBC |
| Conditions Active | TBC |
| Conditions Discontinued | TBC |
| Notes | TBC |
Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]
SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]
Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]
